Literature DB >> 29112784

Clinical and genetic features of patients with facial-sparing facioscapulohumeral muscular dystrophy.

J-J He1, X-D Lin1, F Lin1, G-R Xu1, L-Q Xu1, W Hu1, D-N Wang1, H-X Lin1, M-T Lin1, N Wang1,2, Z-Q Wang1,2.   

Abstract

BACKGROUND AND
PURPOSE: Facial-sparing scapular myopathy (SHD) is the most common atypical form of facioscapulohumeral muscular dystrophy (FSHD), clinically defined as without apparent facial muscle weakness on neurological examination. The clinical profiles and genetic features of SHD are limited.
METHODS: A cohort of 21 Chinese patients with SHD were confirmed by molecular genetic analysis based on pulsed-field gel electrophoresis. The clinical assessments and methylation analysis were noted.
RESULTS: The patients had FSHD-related EcoRI fragments with 4qA haplotype ranging from 18 kb to 33 kb (mean 26.3 ± 4.6 kb). The mean onset age was 25.52 ± 8.3 years. Over half of the patients had scapular winging and asymmetry weakness consistent with FSHD, without facial symptoms during their visit. Their facial electromyogram results were almost normal or mild myogenic damage, as well as the myopathology and serum creatine kinase. A conflict was unexpectedly found in intergenerational DR1 methylation analysis.
CONCLUSION: Facial-sparing scapular myopathy is characterized as mild myopathic symptoms and chronic progression of weakness. The diagnosis should be accurately confirmed through FSHD-sized fragment detection and 4qA/B variant determination. Although the next generations of SHD had more severe muscular symptoms, local hypomethylation within D4Z4 was not found as a modifier for clinical heterogeneity.
© 2017 EAN.

Entities:  

Keywords:  4qA/4qB determination; D4Z4 repeats; facial-sparing scapular myopathy ; hypomethylation; molecular analysis

Mesh:

Year:  2017        PMID: 29112784     DOI: 10.1111/ene.13509

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  9 in total

Review 1.  FSHD Therapeutic Strategies: What Will It Take to Get to Clinic?

Authors:  Charis L Himeda; Peter L Jones
Journal:  J Pers Med       Date:  2022-05-25

2.  A family-based study into penetrance in facioscapulohumeral muscular dystrophy type 1.

Authors:  Mariëlle Wohlgemuth; Richard J Lemmers; Marianne Jonker; Elly van der Kooi; Corinne G Horlings; Baziel G van Engelen; Silvere M van der Maarel; George W Padberg; Nicol C Voermans
Journal:  Neurology       Date:  2018-07-11       Impact factor: 9.910

3.  Large genotype-phenotype study in carriers of D4Z4 borderline alleles provides guidance for facioscapulohumeral muscular dystrophy diagnosis.

Authors:  Giulia Ricci; Fabiano Mele; Monica Govi; Lucia Ruggiero; Francesco Sera; Liliana Vercelli; Cinzia Bettio; Lucio Santoro; Tiziana Mongini; Luisa Villa; Maurizio Moggio; Massimiliano Filosto; Marina Scarlato; Stefano C Previtali; Silvia Maria Tripodi; Elena Pegoraro; Roberta Telese; Antonio Di Muzio; Carmelo Rodolico; Elisabetta Bucci; Giovanni Antonini; Maria Grazia D'Angelo; Angela Berardinelli; Lorenzo Maggi; Rachele Piras; Maria Antonietta Maioli; Gabriele Siciliano; Giuliano Tomelleri; Corrado Angelini; Rossella Tupler
Journal:  Sci Rep       Date:  2020-12-10       Impact factor: 4.379

4.  Prevalence and disease progression of genetically-confirmed facioscapulohumeral muscular dystrophy type 1 (FSHD1) in China between 2001 and 2020: a nationwide population-based study.

Authors:  Zhiqiang Wang; Liangliang Qiu; Minting Lin; Long Chen; Fuze Zheng; Lin Lin; Feng Lin; Zhixian Ye; Xiaodan Lin; Junjie He; Lili Wang; Xin Lin; Qifang He; Wanjin Chen; Yi Lin; Ying Fu; Ning Wang
Journal:  Lancet Reg Health West Pac       Date:  2021-11-22

Review 5.  Outcome Measures in Facioscapulohumeral Muscular Dystrophy Clinical Trials.

Authors:  Mehdi Ghasemi; Charles P Emerson; Lawrence J Hayward
Journal:  Cells       Date:  2022-02-16       Impact factor: 6.600

6.  A "Triple Trouble" Case of Facioscapulohumeral Muscular Dystrophy Accompanied by Peripheral Neuropathy and Myoclonic Epilepsy.

Authors:  Xiao-Dan Lin; Jun-Jie He; Feng Lin; Hai-Zhu Chen; Liu-Qing Xu; Wei Hu; Nai-Qing Cai; Min-Ting Lin; Ning Wang; Zhi-Qiang Wang; Guo-Rong Xu
Journal:  Chin Med J (Engl)       Date:  2018-09-20       Impact factor: 2.628

7.  Rapid prenatal diagnosis of Facioscapulohumeral Muscular Dystrophy 1 by combined Bionano optical mapping and karyomapping.

Authors:  Yuting Zheng; Lingrong Kong; Hui Xu; Yongjie Lu; Xuechao Zhao; Yuxia Yang; Guoliang Yu; Pidong Li; Fan Liang; Hongshuai Jin; Xiangdong Kong
Journal:  Prenat Diagn       Date:  2019-12-02       Impact factor: 3.050

8.  A 5-year clinical follow-up study from the Italian National Registry for FSHD.

Authors:  Liliana Vercelli; Fabiano Mele; Lucia Ruggiero; Francesco Sera; Silvia Tripodi; Giulia Ricci; Antonio Vallarola; Luisa Villa; Monica Govi; Louise Maranda; Antonio Di Muzio; Marina Scarlato; Elisabetta Bucci; Lorenzo Maggi; Carmelo Rodolico; Maurizio Moggio; Massimiliano Filosto; Giovanni Antonini; Stefano Previtali; Corrado Angelini; Angela Berardinelli; Elena Pegoraro; Gabriele Siciliano; Giuliano Tomelleri; Lucio Santoro; Tiziana Mongini; Rossella Tupler
Journal:  J Neurol       Date:  2020-08-19       Impact factor: 4.849

9.  Characterizing the face in facioscapulohumeral muscular dystrophy.

Authors:  T G J Loonen; C G C Horlings; S C C Vincenten; C H G Beurskens; S Knuijt; G W A M Padberg; J M Statland; N C Voermans; T J J Maal; B G M van Engelen; K Mul
Journal:  J Neurol       Date:  2020-10-28       Impact factor: 4.849

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.